Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation. Many tumors can upregulate expression of PD-L1, inhibiting antitumor T-cell responses and avoiding immune surveillance and elimination. We have identified and characterized MEDI4736, a human IgG1 monoclonal antibody that binds with high affinity and specificity to PD-L1 and is ...

Parkinson’s disease (PD) is the most common neurological globally, only second to Alzheimer’s disease. One of emerging treatments for PD nutraceuticals. Grape seed extract (GSE) has a high concentration polyphenolic compounds possessing antioxidant and neuroprotective capacity that may be valuable neurodegenerative diseases. So far, there no review summarizing effect GSE on PD, even though it c...

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the role of the programmed death-1 (PD-1) pathway in chronic GVHD using a well-defined mouse model of B10.D2 (H-2(d)) donor to BALB/c (H-2(d)) recipients. PD-1 expression on allogeneic donor T cells was u...

BACKGROUND Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination of three distinct immunotherapies: a class I restricted peptide-based cancer vaccine, metronomic cyclophosphamide (mCPA) and anti-PD-1 treatment in a murine tumor model expressi...

Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of advanced hepatocellular carcinoma (HCC) are ongoing. Expansion cohorts of a phase I/II trial of the anti-PD-1 antibody nivolumab in advanced HCC showed favorable results. Two ...

in the present study, we investigated the effect of a new anticancer pd(ii) complex, 1,10-phenanthroline-n-butyl dithiocarbamato pd(ii) nitrate, on the heme releasing from human hemoglobin (hb) as well as alterations in the structure and function of hb using different spectroscopic methods of uv-vis, fluorescence and circular dichroism (cd)at two temperatures of 25 and 37 °c. fluorescence data ...

Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. According to recent clinical studies, tumour growth can be effectively reduced and survival can be improved by blocking the programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD‑L1) pathway. PD-L1 expression has been proposed as a potential causative mechan...

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (PD42)1 Sep 2021PD42-06 BOOSTING THE COMBINATION OF RADIATION AND ANTI-PD-L1 WITH STING AGONIST IN A PRECLINICAL MUSCLE INVASIVE BLADDER CANCER MURINE MODEL Gautier Marcq, Jiamin Huang, Côme Tholomier, Surashri Shinde-Jadhav, Ronald Kool, Rodrigo Skowronski, Fadi Brimo, Jose Joao Mansure, and Wassim Kassouf Mar...